Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy
Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has lim...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.855474/full |
| _version_ | 1828365203914358784 |
|---|---|
| author | Hong Dai Hong Dai Razack Abdullah Razack Abdullah Xiaoqiu Wu Xiaoqiu Wu Fangfei Li Fangfei Li Fangfei Li Yuan Ma Yuan Ma Yuan Ma Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang |
| author_facet | Hong Dai Hong Dai Razack Abdullah Razack Abdullah Xiaoqiu Wu Xiaoqiu Wu Fangfei Li Fangfei Li Fangfei Li Yuan Ma Yuan Ma Yuan Ma Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang |
| author_sort | Hong Dai |
| collection | DOAJ |
| description | Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy. |
| first_indexed | 2024-04-14T05:27:47Z |
| format | Article |
| id | doaj.art-f5236934290b4ac6a85cba939f7c98aa |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-04-14T05:27:47Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-f5236934290b4ac6a85cba939f7c98aa2022-12-22T02:09:56ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2022-05-011010.3389/fcell.2022.855474855474Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted TherapyHong Dai0Hong Dai1Razack Abdullah2Razack Abdullah3Xiaoqiu Wu4Xiaoqiu Wu5Fangfei Li6Fangfei Li7Fangfei Li8Yuan Ma9Yuan Ma10Yuan Ma11Aiping Lu12Aiping Lu13Aiping Lu14Ge Zhang15Ge Zhang16Ge Zhang17Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute for the Advancement of Chinese medicine (IACM) .Ltd, Shatin, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaInstitute of Precision Medicine and Innovative Drug Discovery, HKBU Institute for Research and Continuing Education, Shenzhen, ChinaPancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy.https://www.frontiersin.org/articles/10.3389/fcell.2022.855474/fullpancreatic cancernucleic acid drugstargeted therapyaptamer-drug conjugatesantisense oligonucleotidessmall interfering RNAs |
| spellingShingle | Hong Dai Hong Dai Razack Abdullah Razack Abdullah Xiaoqiu Wu Xiaoqiu Wu Fangfei Li Fangfei Li Fangfei Li Yuan Ma Yuan Ma Yuan Ma Aiping Lu Aiping Lu Aiping Lu Ge Zhang Ge Zhang Ge Zhang Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy Frontiers in Cell and Developmental Biology pancreatic cancer nucleic acid drugs targeted therapy aptamer-drug conjugates antisense oligonucleotides small interfering RNAs |
| title | Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy |
| title_full | Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy |
| title_fullStr | Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy |
| title_full_unstemmed | Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy |
| title_short | Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy |
| title_sort | pancreatic cancer nucleic acid drug discovery and targeted therapy |
| topic | pancreatic cancer nucleic acid drugs targeted therapy aptamer-drug conjugates antisense oligonucleotides small interfering RNAs |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2022.855474/full |
| work_keys_str_mv | AT hongdai pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT hongdai pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT razackabdullah pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT razackabdullah pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT xiaoqiuwu pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT xiaoqiuwu pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT fangfeili pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT fangfeili pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT fangfeili pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT yuanma pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT yuanma pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT yuanma pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT aipinglu pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT aipinglu pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT aipinglu pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT gezhang pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT gezhang pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy AT gezhang pancreaticcancernucleicaciddrugdiscoveryandtargetedtherapy |